Eprilic Capsule SR is a sustained-release formulation combining Eperisone 150 mg and Diclofenac 100 mg, designed for the management of musculoskeletal disorders characterized by muscle spasm and inflammation. Eperisone is a centrally acting muscle relaxant that alleviates muscle stiffness and improves blood flow by inhibiting spinal reflexes, thereby reducing muscle spasticity and associated pain. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, leading to decreased prostaglandin synthesis. The synergistic action of these two agents provides effective relief from pain, inflammation, and muscle rigidity commonly observed in conditions such as cervical spondylosis, lumbar spondylosis, myositis, and other soft tissue injuries. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance by reducing dosing frequency. Eprilic Capsule SR should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, active gastrointestinal ulcers, or severe hepatic or renal impairment. Common adverse effects may include gastrointestinal discomfort, dizziness, or allergic reactions. Patients are advised to report any unusual symptoms promptly. This combination therapy offers a comprehensive approach to managing musculoskeletal pain and improving functional mobility in affected individuals.